![](/img/cover-not-exists.png)
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Vena, F., Li Causi, E., Rodriguez-Justo, M., Goodstal, S., Hagemann, T., Hartley, J. A., Hochhauser, D.Volume:
21
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.ccr-15-0485
Date:
December, 2015
File:
PDF, 3.16 MB
english, 2015